Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

被引：0
|
作者：
Backes, Floor [1 ]
Wei, Lai [1 ]
Copeland, Larry [1 ]
Cohn, David [1 ]
Fowler, Jeffrey [1 ]
Bixel, Kristin [1 ]
Cosgrove, Casey [1 ]
Hays, John [1 ]
Myers, Molly [1 ]
Dodd, Kelly [1 ]
O'Malley, David [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [1] PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    Backes, F.
    Fowler, J.
    Copeland, L.
    Wei, L.
    O'Malley, D.
    Cohn, D.
    Cosgrove, C.
    Hays, J.
    Bixel, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A13 - A14
  • [2] Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
    Gonzalez-Ochoa, Eduardo
    Veneziani, Ana C.
    Oza, Amit M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [3] Mirvetuximab Soravtansine for platinum-resistant Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (08) : 882 - 882
  • [4] A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
    Cristea, Mihaela C.
    Stewart, Daphne
    Synold, Timothy
    Ruel, Nora
    Mortimer, Joanne
    Wang, Edward
    Jung, Alexander
    Wilczynski, Sharon
    Konecny, Gottfried E.
    Eng, Melissa
    Kilpatrick, Lindsay
    Han, Ernest
    Dellinger, Thanh
    Hakim, Amy
    Lee, Stephen
    Morgan, Robert J.
    Wakabayashi, Mark T.
    Frankel, Paul H.
    GYNECOLOGIC ONCOLOGY, 2024, 182 : 124 - 131
  • [5] Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer
    Porter, Rebecca L.
    Matulonis, Ursula A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 783 - 796
  • [6] Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
    Moore, K. N.
    Angelergues, A.
    Konecny, G. E.
    Garcia, Y.
    Banerjee, S.
    Lorusso, D.
    Lee, J. -Y.
    Moroney, J. W.
    Colombo, N.
    Roszak, A.
    Tromp, J.
    Myers, T.
    Lee, J. -W.
    Beiner, M.
    Cosgrove, C. M.
    Cibula, D.
    Martin, L. P.
    Sabatier, R.
    Buscema, J.
    Estevez-Garcia, P.
    Coffman, L.
    Nicum, S.
    Duska, L. R.
    Pignata, S.
    Galvez, F.
    Wang, Y.
    Method, M.
    Berkenblit, A.
    Roufai, D. Bello
    Van Gorp, T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2162 - 2174
  • [7] FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
    Moore, Kathleen N.
    Vergote, Ignace
    Oaknin, Ana
    Colombo, Nicoletta
    Banerjee, Susana
    Oza, Amit
    Pautier, Patricia
    Malek, Karim
    Birrer, Michael J.
    FUTURE ONCOLOGY, 2018, 14 (17) : 1669 - 1678
  • [8] A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
    Moore, Kathleen N.
    Martin, Lainie P.
    O'Malley, David M.
    Matulonis, Ursula A.
    Konner, Jason A.
    Vergote, Ignace
    Ponte, Jose F.
    Birrer, Michael J.
    FUTURE ONCOLOGY, 2018, 14 (02) : 123 - 136
  • [9] Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
    Wu, Yong
    Xia, Lingfang
    Song, Chunyan
    Chen, Xiaojun
    Wu, Xiaohua
    JOURNAL OF OVARIAN RESEARCH, 2025, 18 (01)
  • [10] Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (02) : 83 - 83
12345